Skip to content

Study · Non-randomized trial · 2022

12 results

Efficacy of iGlarLixi in adults with type 2 diabetes inadequately controlled (glycated haemoglobin ≥8%, ≥64 mmol/mol) on two oral antidiabetes drugs: Post hoc analysis of the LixiLan-O randomized trial.

Davies MJ, Rosenstock J, Ali A, Russell-Jones D, Souhami E, Palmer K, Ji C, Niemoeller E, Skolnik N

Diabetes, obesity & metabolism6 Oct 2021Cited by 2 (Europe PMC)

PMID34617398 (opens in a new tab)PMCIDPMC9293415 (opens in a new tab)DOI10.1111/dom.14543 (opens in a new tab)PepBankPUB-34617398
Read at sourcePubMedAsk about this study
Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. 12 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In adults with type 2 diabetes, baseline HbA1c of 8% or more and metformin plus a second oral drug, HbA1c fell by 1.9% (20 mmol/mol) with iGlarLixi versus 1.6% (17 mmol/mol) with glargine.

    In plain wordsIn adults with diabetes and HbA1c of 8% or more, adding lixisenatide reduced HbA1c more than glargine alone.

    Peptide
    Lixisenatide
    Outcome
    DecreaseHbA1c reduction
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Analysis
    Exploratory
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    HbA1c change from baseline
    −1.9%
    iGlarLixi
    HbA1c change from baseline
    −1.6%
    iGlar
    HbA1c change from baseline
    −20 mmol/mol
    iGlarLixi
    HbA1c change from baseline
    −17 mmol/mol
    iGlar

    Source sentences

    Summary
    iGlarLixi demonstrated greater mean reductions from baseline in HbA1c and 2-hour postprandial glucose (PPG) compared with iGlar or Lixi (HbA1c -1.9% vs. -1.6% or -1.0% [-20 vs. -17 or -10 mmol/mol; 2-hour PPG -7.2 vs. -4.6 or -5.5 mmol/L).
    2 context sentences
    Summary · context
    The LixiLan-O study (NCT02058147) compared iGlarLixi with iGlar or Lixi in adults with T2D inadequately controlled on metformin ± a second oral antidiabetes drug (OAD).
    Summary · context
    This exploratory analysis evaluated the LixiLan-O subgroup of participants with baseline HbA1c levels of ≥8% (≥64 mmol/mol) who were receiving metformin plus a second OAD at screening.
  2. 02HumanNon-randomized trialEfficacy outcome

    In adults with type 2 diabetes, baseline HbA1c of 8% or more and metformin plus a second oral drug, two-hour PPG fell by 7.2 mmol/L with iGlarLixi versus 4.6 mmol/L with glargine.

    In plain wordsIn adults with diabetes and HbA1c of 8% or more, adding lixisenatide reduced after-meal glucose more than glargine alone.

    Peptide
    Lixisenatide
    Outcome
    DecreaseTwo-hour postprandial glucose reduction
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Analysis
    Exploratory
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    2-hour PPG change from baseline
    −7.2 mmol/L
    iGlarLixi
    2-hour PPG change from baseline
    −4.6 mmol/L
    iGlar

    Source sentences

    Summary
    iGlarLixi demonstrated greater mean reductions from baseline in HbA1c and 2-hour postprandial glucose (PPG) compared with iGlar or Lixi (HbA1c -1.9% vs. -1.6% or -1.0% [-20 vs. -17 or -10 mmol/mol; 2-hour PPG -7.2 vs. -4.6 or -5.5 mmol/L).
    2 context sentences
    Summary · context
    The LixiLan-O study (NCT02058147) compared iGlarLixi with iGlar or Lixi in adults with T2D inadequately controlled on metformin ± a second oral antidiabetes drug (OAD).
    Summary · context
    This exploratory analysis evaluated the LixiLan-O subgroup of participants with baseline HbA1c levels of ≥8% (≥64 mmol/mol) who were receiving metformin plus a second OAD at screening.
  3. 03HumanNon-randomized trialEfficacy outcome

    In adults with type 2 diabetes, baseline HbA1c of 8% or more and metformin plus a second oral drug, 67% receiving iGlarLixi versus 51% receiving glargine achieved HbA1c <7% (<53 mmol/mol).

    In plain wordsIn adults with diabetes and HbA1c of 8% or more, more participants reached the HbA1c target with added lixisenatide than glargine alone.

    Peptide
    Lixisenatide
    Outcome
    IncreaseHbA1c below 7% response
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Analysis
    Exploratory
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Participants with HbA1c <7%
    67%
    iGlarLixi
    Participants with HbA1c <7%
    51%
    iGlar

    Source sentences

    Summary
    Greater proportions of participants achieved HbA1c <7% (<53 mmol/mol) with iGlarLixi versus iGlar or Lixi (67% vs. 51% or 18%)
    2 context sentences
    Summary · context
    The LixiLan-O study (NCT02058147) compared iGlarLixi with iGlar or Lixi in adults with T2D inadequately controlled on metformin ± a second oral antidiabetes drug (OAD).
    Summary · context
    This exploratory analysis evaluated the LixiLan-O subgroup of participants with baseline HbA1c levels of ≥8% (≥64 mmol/mol) who were receiving metformin plus a second OAD at screening.
  4. 04HumanNon-randomized trialEfficacy outcome

    In adults with type 2 diabetes, baseline HbA1c of 8% or more and metformin plus a second oral drug, 36% receiving iGlarLixi versus 19% receiving glargine achieved HbA1c <7% without weight gain.

    In plain wordsIn adults with diabetes and HbA1c of 8% or more, more reached the HbA1c target without weight gain with added lixisenatide than glargine alone.

    Peptide
    Lixisenatide
    Outcome
    IncreaseHbA1c target without weight gain
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Analysis
    Exploratory
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Participants with HbA1c <7% and no weight gain
    36%
    iGlarLixi
    Participants with HbA1c <7% and no weight gain
    19%
    iGlar

    Source sentences

    Summary
    and the composite endpoints of HbA1c <7% (<53 mmol/mol) with no body weight gain (36% vs. 19% or 16%)
    2 context sentences
    Summary · context
    The LixiLan-O study (NCT02058147) compared iGlarLixi with iGlar or Lixi in adults with T2D inadequately controlled on metformin ± a second oral antidiabetes drug (OAD).
    Summary · context
    This exploratory analysis evaluated the LixiLan-O subgroup of participants with baseline HbA1c levels of ≥8% (≥64 mmol/mol) who were receiving metformin plus a second OAD at screening.
  5. 05HumanNon-randomized trialEfficacy outcome

    In adults with type 2 diabetes, baseline HbA1c of 8% or more and metformin plus a second oral drug, 28% receiving iGlarLixi versus 15% receiving glargine achieved HbA1c <7% without weight gain or documented symptomatic hypoglycaemia.

    In plain wordsIn adults with diabetes and HbA1c of 8% or more, more reached the target without weight gain or hypoglycaemia with added lixisenatide than glargine alone.

    Peptide
    Lixisenatide
    Outcome
    IncreaseHbA1c target without weight gain or symptomatic hypoglycaemia
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Analysis
    Exploratory
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Participants with HbA1c <7%, no weight gain and no documented symptomatic hypoglycaemia
    28%
    iGlarLixi
    Participants with HbA1c <7%, no weight gain and no documented symptomatic hypoglycaemia
    15%
    iGlar

    Source sentences

    Summary
    and HbA1c <7% (<53 mmol/mol) with no body weight gain and no documented symptomatic hypoglycaemia (plasma glucose ≤3.9 mmol/L; 28% vs. 15% or 15%).
    2 context sentences
    Summary · context
    The LixiLan-O study (NCT02058147) compared iGlarLixi with iGlar or Lixi in adults with T2D inadequately controlled on metformin ± a second oral antidiabetes drug (OAD).
    Summary · context
    This exploratory analysis evaluated the LixiLan-O subgroup of participants with baseline HbA1c levels of ≥8% (≥64 mmol/mol) who were receiving metformin plus a second OAD at screening.
  6. 06HumanNon-randomized trialSafety outcome

    In adults with type 2 diabetes, baseline HbA1c of 8% or more and metformin plus a second oral drug, documented symptomatic hypoglycaemia occurred in 29.0% receiving iGlarLixi versus 27.9% receiving glargine.

    In plain wordsIn adults with diabetes and HbA1c of 8% or more, symptomatic hypoglycaemia was numerically more frequent with added lixisenatide than glargine alone.

    Peptide
    Lixisenatide
    Outcome
    IncreaseDocumented symptomatic hypoglycaemia versus glargine
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Analysis
    Exploratory
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Documented symptomatic hypoglycaemia incidence
    29%
    iGlarLixi
    Documented symptomatic hypoglycaemia incidence
    27.9%
    iGlar

    Source sentences

    Summary
    The incidence rates of documented symptomatic hypoglycaemia were 29.0%, 27.9% and 12.1% for iGlarLixi, iGlar and Lixi, respectively.
    2 context sentences
    Summary · context
    The LixiLan-O study (NCT02058147) compared iGlarLixi with iGlar or Lixi in adults with T2D inadequately controlled on metformin ± a second oral antidiabetes drug (OAD).
    Summary · context
    This exploratory analysis evaluated the LixiLan-O subgroup of participants with baseline HbA1c levels of ≥8% (≥64 mmol/mol) who were receiving metformin plus a second OAD at screening.
  7. 07HumanNon-randomized trialSafety outcome

    In adults with type 2 diabetes, baseline HbA1c of 8% or more and metformin plus a second oral drug, documented symptomatic hypoglycaemia occurred in 12.1% receiving lixisenatide alone.

    In plain wordsIn adults with diabetes and HbA1c of 8% or more, 12.1% receiving lixisenatide alone had documented symptomatic hypoglycaemia.

    Peptide
    Lixisenatide
    Outcome
    Direction not reportedDocumented symptomatic hypoglycaemia with lixisenatide alone
    Study

    n: not reported in source

    Analysis
    Exploratory
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Documented symptomatic hypoglycaemia incidence
    12.1%
    Lixi alone

    Source sentences

    Summary
    The incidence rates of documented symptomatic hypoglycaemia were 29.0%, 27.9% and 12.1% for iGlarLixi, iGlar and Lixi, respectively.
    2 context sentences
    Summary · context
    The LixiLan-O study (NCT02058147) compared iGlarLixi with iGlar or Lixi in adults with T2D inadequately controlled on metformin ± a second oral antidiabetes drug (OAD).
    Summary · context
    This exploratory analysis evaluated the LixiLan-O subgroup of participants with baseline HbA1c levels of ≥8% (≥64 mmol/mol) who were receiving metformin plus a second OAD at screening.
  8. 08HumanNon-randomized trialEfficacy outcome

    In adults with type 2 diabetes, baseline HbA1c of 8% or more and metformin plus a second oral drug, HbA1c fell by 1.0% (10 mmol/mol) from baseline with lixisenatide alone.

    In plain wordsIn adults with diabetes and HbA1c of 8% or more, HbA1c decreased from baseline with lixisenatide alone.

    Peptide
    Lixisenatide
    Outcome
    DecreaseHbA1c change with lixisenatide alone
    Study

    n: not reported in source

    Analysis
    Exploratory
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    HbA1c change from baseline
    −1%
    Lixi alone
    HbA1c change from baseline
    −10 mmol/mol
    Lixi alone

    Source sentences

    Summary
    iGlarLixi demonstrated greater mean reductions from baseline in HbA1c and 2-hour postprandial glucose (PPG) compared with iGlar or Lixi (HbA1c -1.9% vs. -1.6% or -1.0% [-20 vs. -17 or -10 mmol/mol; 2-hour PPG -7.2 vs. -4.6 or -5.5 mmol/L).
    2 context sentences
    Summary · context
    The LixiLan-O study (NCT02058147) compared iGlarLixi with iGlar or Lixi in adults with T2D inadequately controlled on metformin ± a second oral antidiabetes drug (OAD).
    Summary · context
    This exploratory analysis evaluated the LixiLan-O subgroup of participants with baseline HbA1c levels of ≥8% (≥64 mmol/mol) who were receiving metformin plus a second OAD at screening.
  9. 09HumanNon-randomized trialEfficacy outcome

    In adults with type 2 diabetes, baseline HbA1c of 8% or more and metformin plus a second oral drug, two-hour PPG fell by 5.5 mmol/L from baseline with lixisenatide alone.

    In plain wordsIn adults with diabetes and HbA1c of 8% or more, after-meal glucose decreased from baseline with lixisenatide alone.

    Peptide
    Lixisenatide
    Outcome
    DecreaseTwo-hour PPG change with lixisenatide alone
    Study

    n: not reported in source

    Analysis
    Exploratory
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    2-hour PPG change from baseline
    −5.5 mmol/L
    Lixi alone

    Source sentences

    Summary
    iGlarLixi demonstrated greater mean reductions from baseline in HbA1c and 2-hour postprandial glucose (PPG) compared with iGlar or Lixi (HbA1c -1.9% vs. -1.6% or -1.0% [-20 vs. -17 or -10 mmol/mol; 2-hour PPG -7.2 vs. -4.6 or -5.5 mmol/L).
    2 context sentences
    Summary · context
    The LixiLan-O study (NCT02058147) compared iGlarLixi with iGlar or Lixi in adults with T2D inadequately controlled on metformin ± a second oral antidiabetes drug (OAD).
    Summary · context
    This exploratory analysis evaluated the LixiLan-O subgroup of participants with baseline HbA1c levels of ≥8% (≥64 mmol/mol) who were receiving metformin plus a second OAD at screening.
  10. 10HumanNon-randomized trialEfficacy outcome

    In adults with type 2 diabetes, baseline HbA1c of 8% or more and metformin plus a second oral drug, 18% receiving lixisenatide alone achieved HbA1c <7% (<53 mmol/mol).

    In plain wordsIn adults with diabetes and HbA1c of 8% or more, 18% receiving lixisenatide alone reached the HbA1c target.

    Peptide
    Lixisenatide
    Outcome
    Not applicableHbA1c target with lixisenatide alone
    Study

    n: not reported in source

    Analysis
    Exploratory
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Participants with HbA1c <7%
    18%
    Lixi alone

    Source sentences

    Summary
    Greater proportions of participants achieved HbA1c <7% (<53 mmol/mol) with iGlarLixi versus iGlar or Lixi (67% vs. 51% or 18%)
    2 context sentences
    Summary · context
    The LixiLan-O study (NCT02058147) compared iGlarLixi with iGlar or Lixi in adults with T2D inadequately controlled on metformin ± a second oral antidiabetes drug (OAD).
    Summary · context
    This exploratory analysis evaluated the LixiLan-O subgroup of participants with baseline HbA1c levels of ≥8% (≥64 mmol/mol) who were receiving metformin plus a second OAD at screening.
  11. 11HumanNon-randomized trialEfficacy outcome

    In adults with type 2 diabetes, baseline HbA1c of 8% or more and metformin plus a second oral drug, 16% receiving lixisenatide alone achieved HbA1c <7% without weight gain.

    In plain wordsIn adults with diabetes and HbA1c of 8% or more, 16% receiving lixisenatide alone reached the HbA1c target without weight gain.

    Peptide
    Lixisenatide
    Outcome
    Not applicableHbA1c target without weight gain with lixisenatide alone
    Study

    n: not reported in source

    Analysis
    Exploratory
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Participants with HbA1c <7% and no weight gain
    16%
    Lixi alone

    Source sentences

    Summary
    and the composite endpoints of HbA1c <7% (<53 mmol/mol) with no body weight gain (36% vs. 19% or 16%)
    2 context sentences
    Summary · context
    The LixiLan-O study (NCT02058147) compared iGlarLixi with iGlar or Lixi in adults with T2D inadequately controlled on metformin ± a second oral antidiabetes drug (OAD).
    Summary · context
    This exploratory analysis evaluated the LixiLan-O subgroup of participants with baseline HbA1c levels of ≥8% (≥64 mmol/mol) who were receiving metformin plus a second OAD at screening.
  12. 12HumanNon-randomized trialEfficacy outcome

    In adults with type 2 diabetes, baseline HbA1c of 8% or more and metformin plus a second oral drug, 15% receiving lixisenatide alone achieved HbA1c <7% without weight gain or documented symptomatic hypoglycaemia.

    In plain wordsIn adults with diabetes and HbA1c of 8% or more, 15% receiving lixisenatide alone reached the HbA1c target without weight gain or symptomatic hypoglycaemia.

    Peptide
    Lixisenatide
    Outcome
    Not applicableTriple target with lixisenatide alone
    Study

    n: not reported in source

    Analysis
    Exploratory
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Participants with HbA1c <7%, no weight gain and no documented symptomatic hypoglycaemia
    15%
    Lixi alone

    Source sentences

    Summary
    and HbA1c <7% (<53 mmol/mol) with no body weight gain and no documented symptomatic hypoglycaemia (plasma glucose ≤3.9 mmol/L; 28% vs. 15% or 15%).
    2 context sentences
    Summary · context
    The LixiLan-O study (NCT02058147) compared iGlarLixi with iGlar or Lixi in adults with T2D inadequately controlled on metformin ± a second oral antidiabetes drug (OAD).
    Summary · context
    This exploratory analysis evaluated the LixiLan-O subgroup of participants with baseline HbA1c levels of ≥8% (≥64 mmol/mol) who were receiving metformin plus a second OAD at screening.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.